Daily pharma scoop: $ACAD growth potential

ACADIA (ACAD) is a company that has a single drug in its pipeline - pimavanserin, brand name Nuplazid. Nuplazid was approved in March for treating Parkinson’s Disease Psychosis or PDP, which are symptomatic delusions and hallucinations associated with Parkinson’s Disease.

The full unabridged post can be accessed on our SeekingAlpha Marketplace page.